Advertisement
U.S. markets closed
Advertisement

Mesoblast Ltd (LWBA.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
1.10000.0000 (0.00%)
At close: 07:31PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close1.1000
Open1.1200
Bid1.1000 x N/A
Ask1.1400 x N/A
Day's Range1.1000 - 1.1300
52 Week Range1.0800 - 4.4600
Volume1,000
Avg. Volume30
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for LWBA.DU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

      NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee. Ms Bell joined the Board in August 2022, and is a banking and finance lawyer with 30 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Austral

    • The Wall Street Journal

      Health Care Roundup: Market Talk

      Find insight on Ikena Oncology, ATS’s acquisition of Avidity Science, and more in the latest Market Talks covering the Health Care sector.

    • GlobeNewswire

      Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval

      NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-L in the treatment of pediatric and adult steroid-refractory acute graft versus host disease (SR-aGVHD), following a Type A meeting held with the United States Food and Drug Administration (FDA). FDA clarified that the key remaining issue for pedi